How effective is Baricitinib in treating vitiligo?

Baricitinib is not currently approved for the treatment of vitiligo. Baricitinib is a Janus kinase (JAK) inhibitor primarily used to treat arthritis and other autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus.

Vitiligo is an autoimmune disease characterized by the appearance of white spots on the skin with loss of pigment. Currently, baricitinib has not been approved for the treatment of vitiligo, and its safety and efficacy in the treatment of vitiligo have not been fully studied and verified.

For the treatment of vitiligo, common methods include topical hormone therapy, phototherapy, oral immunomodulators, etc. The effectiveness of treatment varies among individuals, and no single treatment works for all patients. If you suffer from vitiligo, it is recommended that you consult a dermatologist or doctor for the most appropriate treatment advice and options. They can evaluate and provide the best treatment options for your specific situation.

Baricitinib has been launched in China and is included in medical insurance. Patients can purchase it domestically. Due to different medical insurance reimbursement policies in different regions, the reimbursement ratio is also different. The price is about 1200~1600 yuan. For specific prices, please consult the local pharmacy or the medical insurance bureau. Baricitinib has both original and generic drugs abroad. The original drug is mainly Eli Lilly’s original drug, and its price is higher than in China. Generic drugs are mainly Bangladeshi generic drugs, and the price is around 450 yuan. The ingredients of original drugs and generic drugs are basically the same.

xa0